« Return to News | Drug Sponsors

FDA approves generic Taxotere

Friday, March 11, 2011 01:47 PM

Hospira has won approval for the first U.S. generic version of Sanofi-aventis’ Taxotere cancer drug, according to a Reuters report.

U.S. sales of Taxotere, an infused chemotherapy known generically as docetaxel, were $1.2 billion last year, according to Hospira. JPMorgan analyst Chris Schott said recently that U.S. approval of generic Taxotere was the most important near-term catalyst for Hospira's shares.

Taxotere lost U.S. patent protection in November, but the FDA wanted changes to the packaging and labeling of Hospira's product before granting approval, a Hospira spokesman said.

Sanofi said it has braced for the arrival of generic rivals to Taxotere and included the impact in its 2011 earnings forecast. The French drugmaker's U.S. Taxotere sales slumped 28% in the fourth quarter because wholesalers were anticipating the arrival of a generic.

Hospira, in its 2011 financial forecast, assumed it would be starting U.S. sales of its generic. The company, a maker of injectable drugs, already markets docetaxel in Europe and Australia.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.